Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 17Dermatologic 2Sarcoma 1Other hematologic neoplasm 1Other 1Lymphoid 1Gynecologic 1

Conditions

Lymphoma, Non-Hodgkin 1

Interventions

Rituximab 1401Cyclophosphamide 1305Vincristine 668Doxorubicin 587Etoposide 527Prednisone 510Cytarabine 486fludarabine 469Methotrexate 445Dexamethasone 413fludarabine phosphate 400Lenalidomide 356Filgrastim 343Bendamustine Hydrochloride 282Radiotherapy 267venetoclax 260ibrutinib 258obinutuzumab 235Peripheral Blood Stem Cell Transplantation 234Melphalan 230Granulocyte Colony-Stimulating Factor 215Bortezomib 204Gemcitabine 202Busulfan 188Whole-Body Irradiation 187Mycophenolic Acid 175Tacrolimus 165Specimen Handling 162Magnetic Resonance Spectroscopy 155Calcium Dobesilate 150

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Polyethylene Glycols × Lymphoid × Clear all
NCT01910025 2018-09-18

PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy

Polaris Group

Phase 2 Completed
18 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡